GlaxoSmithKline has signed up to sell Faes Farma's antihistamine bilastine in the latter's home market of Spain and Poland.

The UK drugs giant has actually signed the deal with Faes partner Menarini which holds the licence for the compound in 51 countries, including the European Union and the Commonwealth of Independent States. In September, the German health agency (BfARm), which was acting as the European Medicines Agency rapporteur for bilastine, gave the drug the green lightfor allergic rhinoconjunctivitis and urticaria.

Bilastine is now approved in ten countries in Europe, including Spain. A deal is already in place with Pierre Fabre to co-market in France and Belgium, while Vianex will sell the treatment in Greece. 

Faes has previously noted that the world antihistamine market is worth 4.2 billion euros and Europe makes up a quarter of that. The firm is hoping for a 20% share of the latter market.